Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Aug 31, 2026 to Sep 10, 2026 Interventions modified · Study sites: 71 to 73 Show 2 more changesShow less
    • Interventions modified
    • Study sites: 71 to 73
  2. Interventions modified Start date: Aug 15, 2026 to Aug 31, 2026 · Eligibility criteria expanded, about 9 words · Study sites revised (71) Show 3 more changesShow less
    • Start date: Aug 15, 2026 to Aug 31, 2026
    • Eligibility criteria expanded, about 9 words
    • Study sites revised (71)
  3. Recruitment opened Study sites revised (71)v2 Show 1 more changeShow less
    • Study sites revised (71)

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Trial Details
NCT Number NCT07680764
Lead Sponsor Bristol-Myers Squibb
Conditions Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov